Who is sponsoring NCT04636918?

NCT04636918 is sponsored by Singapore Eye Research Institute.

What drugs are being tested in NCT04636918?

Interventions in NCT04636918: Cyclosporine Ophthalmic.

What condition does NCT04636918 study?

NCT04636918 studies Leukemia (Both ALL and AML), MDS-EB-1.

Is NCT04636918 still recruiting?

NCT04636918 is currently status unknown. Last updated 19 November 2020.

Last reviewed 2020-11-19 · How we verify

NCT04636918: Ikervis

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Ikervis for DED Due to GVHD Post Allo-HSCT

Status unknown Phase 4 Last updated 19 November 2020

What this trial tests

Phase 4 trial testing Cyclosporine Ophthalmic in Leukemia (Both ALL and AML) in 40 participants. Status unknown.

Timeline

28 November 2019

Primary endpoint
22 August 2022

30 December 2022

Quick facts

Lead sponsor	Singapore Eye Research Institute
Phase	Phase 4
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	prevention
Enrollment	40
Start date	28 November 2019
Primary completion	22 August 2022
Estimated completion	30 December 2022
Sites	1 location across Singapore

Drugs / interventions tested

Cyclosporine Ophthalmic — full drug profile →

Conditions studied

Leukemia (Both ALL and AML) — all drugs for Leukemia (Both ALL and AML) →
MDS-EB-1 — all drugs for MDS-EB-1 →

Sponsor

Singapore Eye Research Institute

Who can join

Adults 13 to 95, any sex, with Leukemia (Both ALL and AML) or MDS-EB-1. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Dry eye disease (DED) is a common sequelae of graft versus host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Since Ikervis is reported to be a safe and efficacious treatment of DED associated with chronic GVHD, our study would like to study the efficacy of prophlactic Ikervis in preventing ocular GVHD development.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

Regenerative treatment of ophthalmic diseases with stem cells: Principles, progress, and challenges.
Niu Y, Ji J, Yao K, Fu Q. · · 2024 · cited 25× · PMID 38586868 · DOI 10.1016/j.aopr.2024.02.001
Recent advances in ocular graft-versus-host disease.
Cheng X, Huang R, Huang S, Fan W, et al · · 2023 · cited 24× · PMID 36761771 · DOI 10.3389/fimmu.2023.1092108
Conjunctival T Cell Profile in Allogeneic Hematopoietic Stem Cell Transplant Patients after Instilling Topical Cyclosporine-A 0.1% Cationic Emulsion.
Tong L, Lim EWL, Yeo SWJ, Hou A, et al · · 2023 · cited 7× · PMID 36856978 · DOI 10.1007/s40123-023-00686-0
Tackling visual impairment: emerging avenues in ophthalmology.
Lin F, Su Y, Zhao C, Akter F, et al · · 2025 · cited 4× · PMID 40357281 · DOI 10.3389/fmed.2025.1567159
Tear Cytokine Changes up to One Year After Allogeneic Hematopoietic Stem Cell Transplant: Effect of Daily Topical Cyclosporine-A 0.1% Emulsion.
Tong L, Liu YC, Yeo SWJ, Liu C, et al · · 2025 · cited 1× · PMID 40565378 · DOI 10.3390/ijms26125915

Verify or expand the search:

Other recruiting trials for Leukemia (Both ALL and AML)

Currently open trials in the same condition.

NCT07450872 — Symptom Cluster Heterogeneity and Gut Microbiota Mechanisms in Childhood Cancer Survivors · recruiting

Other Singapore Eye Research Institute trials

Trials by the same sponsor.

NCT06983652 — Validation of the Use of Terahertz Scanning System on Corneal Scars and Corneal Edema · recruiting
NCT06877988 — Artificial Intelligence (AI) - Assisted Visual Impairment Screening Model: Community-based Implementation and Evaluation · NA · active not recruiting
NCT06967792 — Evaluation of the Safety of Terahertz Scanning System on Corneas · recruiting
NCT07174739 — Efficacy of Quantum Molecular Resonance in Neuropathic Corneal Pain and Corneal Nerve Regeneration · NA · recruiting
NCT06774651 — Comparison of Femto LDV Z8 Corneal Lenticule Extraction for Advanced Refractive Correction (CLEAR) and Visumax Small Inc · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04636918 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Singapore Eye Research Institute
Last refreshed: 19 November 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04636918.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing